Coherus BioSciences
CHRSCoherus Oncology is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology therapies.
Table of contents
Earnings
Next report
Aug 5, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Coherus Oncology is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology therapies. The company's core value proposition centers on its approved next-generation PD-1 inhibitor and a clinical pipeline designed to overcome immune resistance in various solid tumors. Following the divestiture of its biosimilar business, the company operates as a specialized oncology entity leveraging U.S.-based clinical development and regulatory expertise.
Coherus holds a first-mover advantage as the provider of the only FDA-approved immune checkpoint inhibitor for nasopharyngeal carcinoma currently available in the U.S.
Questions, answered.
- What is Coherus BioSciences's market cap?
- Coherus BioSciences (CHRS) has a market capitalization of $225.2M and trades on NASDAQ.
- Who are Coherus BioSciences's competitors?
- Coherus BioSciences's key competitors include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
- Who does Coherus BioSciences partner with?
- Coherus BioSciences's notable partners include Junshi Biosciences Co., Ltd., Apotex, Inc., Janssen Research & Development, LLC, and others.
- What subsidiaries does Coherus BioSciences have?
- Coherus BioSciences's subsidiaries include Surface Oncology, Inc..
- Where is Coherus BioSciences headquartered?
- Coherus BioSciences is headquartered in United States of America and employs approximately 306 people. It has been publicly traded since 2014.